Inclusion Criteria:

- Patients with histologic proof of adenocarcinoma of the prostate and must have failed
conventional hormonal therapy.

- Patients must have osteoblastic bone metastases. At least one osteoblastic lesion
must be documented by plain film. Patients with mixed or osteolytic bone metastases
must have a biopsy to exclude histologic variants of prostate cancer or metastasis
from another primary (for phase II only).

- Patients must have evidence of progression of disease as demonstrated by 2
consecutive rise in PSA (an absolute change of at least 1 ng/mL) over 4 weeks.

- Patients on flutamide, nilutamide, or bicalutamide should be discontinued from
flutamide or nilutamide and bicalutamide for at least 4 weeks and 8 weeks,
respectively.

- Patients must have an expected survival of at least three months and a Zubrod
performance status of < 2 (Zubrod scale; Appendix B).

- Patients may receive no concurrent chemotherapy or immunotherapy.

- Patients must have castrate serum testosterone levels (< 30 ng/dl). For patients who
are medically castrated, lutenizing hormone releasing hormone analog must continue to
maintain testicular suppression.

- Patients must have adequate bone marrow function defined as an absolute peripheral
granulocyte count of > 1,500/mm3 and platelet count of > 100,000/mm3; adequate
hepatic function defined with a bilirubin of < 1.5 mg% and SGOT (AST) < 2X the upper
limits of normal; adequate renal function defined as serum creatinine clearance > 40
cc/min (measured or calculated).

- Patients must be >= 18 years old.

- Patients may have received oral EMP or no more than one cytotoxic therapy.

- Patients must sign a written informed consent form prior to treatment.

Exclusion Criteria:

- Patients with severe intercurrent infection.

- Patients with prior exposure to Taxol.

- Patients whose tumors contain small cell or sarcomatoid elements.

- Patients with evidence of conduction block or active myocardial ischemia on ECG.

- Patients with a history of prior malignancy (except noninvasive cutaneous carcinoma).

- Patients with a history of thromboembolism.